Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
54.54
-0.12 (-0.22%)
At close: Jan 17, 2025, 4:00 PM
54.20
-0.34 (-0.62%)
Pre-market: Jan 21, 2025, 7:19 AM EST
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for RYTM stock have an average target of 66.9, with a low estimate of 52 and a high estimate of 80. The average target predicts an increase of 22.66% from the current stock price of 54.54.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RYTM stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 6 | 6 | 6 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $75 | Buy | Reiterates | $75 | +37.51% | Dec 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $69 | Strong Buy | Reiterates | $69 | +26.51% | Dec 23, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $76 | Buy | Initiates | $76 | +39.35% | Dec 20, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $59 → $66 | Strong Buy | Maintains | $59 → $66 | +21.01% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $69 | Strong Buy | Reiterates | $69 | +26.51% | Dec 4, 2024 |
Financial Forecast
Revenue This Year
126.80M
from 77.43M
Increased by 63.77%
Revenue Next Year
183.75M
from 126.80M
Increased by 44.91%
EPS This Year
-4.44
from -3.20
EPS Next Year
-2.64
from -4.44
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 131.8M | 219.0M | 420.0M | |||
| Avg | 126.8M | 183.8M | 327.4M | |||
| Low | 120.7M | 161.4M | 214.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 70.2% | 72.7% | 128.6% | |||
| Avg | 63.8% | 44.9% | 78.2% | |||
| Low | 55.9% | 27.3% | 16.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.22 | -2.13 | 0.02 | |||
| Avg | -4.44 | -2.64 | -0.93 | |||
| Low | -4.53 | -3.10 | -2.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.